• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to project page

2005 Fiscal Year Final Research Report Summary

Anti-tumor effects of angiotensin II type 1 antagonist in hormone-refractory prostate cancer.

Research Project

Project/Area Number 16591621
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeSingle-year Grants
Section一般
Research Field Urology
Research InstitutionKeio University

Principal Investigator

MIYAJIMA Akira  Keio University, School of Medicine, Instructor, 医学部, 助手 (90245572)

Co-Investigator(Kenkyū-buntansha) KOSUGI Michio  Keio University, School of Medicine, Instructor, 医学部, 助手 (10317216)
NAKASHIMA Jun  Keio University, School of Medicine, Associate Professor, 医学部, 助教授 (10167546)
MURAI Masaru  Keio University, School of Medicine, Professor, 医学部, 教授 (90101956)
Project Period (FY) 2004 – 2005
Keywordsprostate cancer / hormone-refractory / angiotensin II / angiogenesis
Research Abstract

We first determined whether hormone-independence is associated with tumor angiogenesis and AT1R expression. Accordingly, we postulated that AT1R blockade may affect angiogenesis in androgen-independent PCa rather than in androgen-dependent Pca, and investigated the effects of AII and candesartan on PCa cell lines and a tumor xenograft model.
A human hormone-refractory PCa (HRPC) and C4-2 androgen-independent PCa cell line showed significantly higher expression of VEGF, MVD, and AT1R than did human androgen-dependent PCa and an LNCaP androgen-dependent PCa cell line. In vitro, AII and candesartan did not directly affect the proliferation of LNCaP and C4-2 cells, but candesartan significantly suppressed VEGF production in C4-2 cells. In vivo, candesartan significantly suppressed VEGF expression, serum PSA concentration and tumor growth (1.1±0.2, 45.0±17.6ng/ml, 235.8±37.4mm3) in C4-2 xenografts in castrated mice, compared with the controls (2.4±0.6, 376.7±74.2ng/ml, 830.8±147.6mm3).
We nest investigated the effects of candesartan in bladder cancer xenograft model, and found similar results in bladder cancer model.

  • Research Products

    (4 results)

All 2006 Other

All Journal Article (4 results)

  • [Journal Article] Angiotensin II type 1 receptor antagonist candesartan as an angiogenic inhibitor in a xenograft model of bladder cancer2006

    • Author(s)
      Kosugi et al.
    • Journal Title

      Clin Cancer Res, 12

      Pages: 2888-2893

    • Description
      「研究成果報告書概要(和文)」より
  • [Journal Article] Angiotensin II type 1 receptor antagonist as an angiogenic inhibitor in prostate cancer2006

    • Author(s)
      Kosaka et al.
    • Journal Title

      Prostate (in press)

    • Description
      「研究成果報告書概要(和文)」より
  • [Journal Article] Angiotensin II type 1 receptor antagonist candesartan as an angiogenic inhibitor in a xenograft model of bladder cancer2006

    • Author(s)
      Kosugi et al.
    • Journal Title

      Clin Cancer Res 12

      Pages: 2888-2893

    • Description
      「研究成果報告書概要(欧文)」より
  • [Journal Article] Angiotensin II type 1 receptor antagonist as an angiogenic inhibitor in prostate cancer

    • Author(s)
      Kosaka T et al.
    • Journal Title

      Prostate (in press)

    • Description
      「研究成果報告書概要(欧文)」より

URL: 

Published: 2007-12-13  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi